Nature Review: Market Forecast of the Global Liver Cancer Drug Market

Market forecast

The liver cancer drug market size is expected to grow from USD870 million (2017) to nearly USD4 billion (2027), which will benefit from the marketing of other 8 high-priced biologics and the extensive promotion of nivolumab as a first-line therapy.

PD-L1 inhibitors are expected to become the variety with the largest market proportion in 2027, with sales to reach USD1.7 billion (Fig. 4) and exceed PD-1 inhibitors, wherein, nearly 50% sales will be from the monotherapies or first-line therapies in combination with tremelimumab for advanced-stage patients, and their use in middle-stage patients will contribute USD320 million income. Atezolizumab (used in combination with bevacizumab) is expected to reach sales of USD530 million in 2027 as a first-line therapy.

PD-1 inhibitors are expected to reach sales of nearly USD1.5 billion in 2027, wherein, nivolumab will reach USD1.1 billion, accounting for above 25% of the entire market in 2027. It will have the largest patient group as a first-line drug, however, the sales of nivolumab as a non-first line therapy are expected to account for 50% of its total sales.

Sales of CTLA4 inhibitor: ipilimumab and tremelimumab (USD320 million in total) are expected to be far lower than those of PD-L1 or PD-1 inhibitors. The sales of those two drugs are associated with the combination with nivolumab or durvalumab. Combined therapies are more effective than monotherapies, however, the drug use will be subject to the safety and tolerance.

Angiogenesis inhibitors’ market share led in 2017, however, although more biological and small molecule angiogenesis inhibitors will be approved, their sales will peak in 2019 and then gradually decline. Generic drugs thereof will affect their future sales potential.

Fig. 4 Market Forecast of Main Immune Inhibitors

Read More:

Nature Review: Current Situation of the Global Liver Cancer Drug Market

Important pipelines in development of the Liver Cancer Drug

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.